2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
在万象更新的2025年伊始,博生吉医药集团开发的、基于Vδ1T细胞的靶向CD19的现货通用型嵌合抗原受体(CAR)-T细胞注射液(研发代号:...
岁序更替,华章日新。转眼间,新年的钟声即将敲响。这一年,是挑战与机遇并存的一年,是创新与突破交织的一年,更是我们携手并进、共创辉煌的一年。每...
近期,备受瞩目的第十三届中国创新创业大赛颠覆性技术创新大赛(以下简称“大赛”)总决赛在杭州市余杭区圆满落幕,在这场汇聚了全国顶尖科技创新项目...
近日,备受瞩目的“合创未来 无限精彩”2024年合创汇年度盛典在合肥高新区圆满落幕,会上正式公布了2024年度新质企业(高成长企业)榜单,博...
Conceptual Pilot Study, Patient Recruitment
Read More